Patents Examined by My-Chau T Tran
  • Amino acid formulations for pancreatic viability
    Patent number: 11224582
    Abstract: Amino acid formulations for pancreatic vitality. The formulations comprise a mixture of a plurality of amino acids, wherein the mixture comprises at least one amino acid selected from the group consisting of serine, glutamic acid, and/or carnitine. Methods of enhancing pancreatic vitality, stabilizing blood glucose levels, and improving A1C levels in subjects in need thereof are also described.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: January 18, 2022
    Assignee: Almeda Labs LLC
    Inventors: Stacy Tucker, Sushrutha Nagaraj
  • Therapeutic agents and methods
    Patent number: 11224599
    Abstract: The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: January 18, 2022
    Inventors: Randice Lisa Altschul, Neil David Theise, Andreas J. Kesel, Myron Rapkin, Rebecca O'Brien, Anthony R. Arment
  • Systems and methods for treatments of an eye with a photosensitizer
    Patent number: 11207410
    Abstract: A formulation for an eye treatment includes a photosensitizer and a permeability enhancing composition. The permeability enhancing composition includes one or more permeability enhancers. The permeability enhancing composition has a hydrophilic and lipophilic balance increases a permeability of an area of the eye for the photosensitizer. The hydrophilic and lipophilic balance can be characterized by a Hydrophile-Lipophile Balance (HLB) number. For example, the area of the eye may include a corneal epithelium, the photosensitizer may include riboflavin, and the permeability enhancing composition may have a corresponding HLB number between approximately 12.6 and approximately 14.6.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: December 28, 2021
    Assignee: Avedro, Inc.
    Inventors: Pavel Kamaev, Marc D. Friedman
  • Methods of reducing apolipoprotein C-III
    Patent number: 11185525
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: November 30, 2021
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Joseph S. Zakrzewski
  • Methods and compositions for the treatment of hair loss
    Patent number: 11166955
    Abstract: Compositions and methods for the treatment of hair growth and the prevention of hair loss.
    Type: Grant
    Filed: April 18, 2021
    Date of Patent: November 9, 2021
    Assignee: Aneira Pharma, Inc.
    Inventor: John Edward Wurst
  • Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer
    Patent number: 11166962
    Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: November 9, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Thomas J. Slaga, Jacob Junco, Huiyun Liang, Sara Reyna
  • Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor
    Patent number: 11166951
    Abstract: Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the ?- and ?-isoforms and selective for both ?- and ?-isoforms (PI3K-?,?, PI3K-?, and PI3K-?), a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a B-cell lymphoma-2 (BCL-2) inhibitor are described. In some embodiments, the invention provides therapeutic combinations of a PI3K-? inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a BCL-2 and BTK inhibitor.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: November 9, 2021
    Assignee: Acerta Pharma B.V.
    Inventors: Ahmed Hamdy, Wayne Rothbaum, Raquel Izumi, Brian Lannutti, Todd Covey, Roger Ulrich, Dave Johnson, Tjeerd Barf, Allard Kaptein
  • Purified compositions of polyunsaturated fatty acids, their preparation method and their use
    Patent number: 11154525
    Abstract: The present invention refers to new purified compositions of long chain polyunsaturated fatty acids, or their salts or esters, characterized by being essentially free from other usually present—but structurally different—components, such as furan fatty acids, phytanic and pristanic acids, squalene, and some oligomers, as well as several “persistent” environmental pollutants, such as polychlorinated dibenzo-dioxins and polychlorinated dibenzo-furans, polychlorinated biphenyls, polybrominated diphenyl-ethers, polycyclic aromatic hydrocarbons, and others, which are also usually present and extremely toxic. The invention also refers to the purification method to obtain said compositions and the use thereof as food, food for special medical use, food and diet supplement, and drug.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: October 26, 2021
    Inventor: Tiberio Bruzzese
  • Creatine and/or creatinine compositions and related methods
    Patent number: 11154499
    Abstract: The disclosure is directed to methods related to creatinine, for example, a method for its safe administration to a human, a method for using creatinine to improve the bioavailability of creatine, and a metn.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: October 26, 2021
    Assignee: THERMOLIFE INTERNATIONAL, LLC
    Inventors: Alexandros Nikolaidis, Ronald Kramer
  • Systems and methods for treatments of an eye with a photosensitizer
    Patent number: 11154618
    Abstract: A formulation for an eye treatment includes a photosensitizer and a permeability enhancing composition. The permeability enhancing composition includes one or more permeability enhancers. The permeability enhancing composition has a hydrophilic and lipophilic balance increases a permeability of an area of the eye for the photosensitizer. The hydrophilic and lipophilic balance can be characterized by a Hydrophile-Lipophile Balance (HLB) number. For example, the area of the eye may include a corneal epithelium, the photosensitizer may include riboflavin, and the permeability enhancing composition may have a corresponding HLB number between approximately 12.6 and approximately 14.6.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: October 26, 2021
    Assignee: Avedro, Inc.
    Inventors: Pavel Kamaev, Marc D. Friedman
  • Regimen for suppressing organ rejection
    Patent number: 11141408
    Abstract: The present invention relates to a method of suppressing organ rejection in a patient receiving an organ transplant by initiating oral treatment with a once-daily extended release tacrolimus dosage form, for example, at an initial dose of from about 0.15 to about 0.20 mg/kg/day within 24 or 48 hours following transplantation. The once-daily extended release tacrolimus dosage form (i) provides low fluctuation and/or swing of tacrolimus, (ii) provides a significantly lower Cmax than an immediate release formulation of tacrolimus while providing the same or greater area under the curve (AUC), (iii) releases the tacrolimus substantially in the colon and/or the lower ileum, (iv) releases at most 63.5% of the tacrolimus in the dosage form at the 12 hour time point, or (v) any combination of any of the foregoing.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: October 12, 2021
    Assignee: VELOXIS PHARMACEUTICALS INC.
    Inventor: William J. Polvino
  • Prophylactic or therapeutic agent for hyperaciive bladder
    Patent number: 11123320
    Abstract: Various side effects are reported for existing overactive bladder therapeutic drugs, and prophylactic or therapeutic agents for overactive bladder without side effects have been eagerly desired. The present invention provides a prophylactic or therapeutic agent for overactive bladder that comprises 5-aminolevulinic acids (ALAs) as the active ingredient.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: September 21, 2021
    Assignees: SBI PHARMACEUTICALS, CO., LTD., NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITY
    Inventors: Tohru Tanaka, Kiwamu Takahashi, Keiji Inoue, Motoaki Saito, Masayuki Tsuda, Hideo Fukuhara, Takahira Kuno, Shogo Shimizu
  • Method for preventing lung diseases in smokers and non-smokers using antihypertensive drug
    Patent number: 11123335
    Abstract: The present invention relates to a method for inhibiting lung diseases in smokers and non-smokers by blocking growth factor signaling using an antihypertensive drug, and more particularly, to a pharmaceutical composition for preventing lung cancer or emphysema, which contains an antihypertensive drug as an active ingredient. The present invention suggests a novel use of an antihypertensive drug which is being used in clinics, to prevent lung diseases, and therefore, may be readily applied to early lung cancer or a lung cancer high-risk group, and particularly may exclude safety concerns accompanying clinical application of novel drugs, thereby increasing clinical applicability. In addition, enormous costs and time needed from development to clinical use of new drugs may be dramatically reduced.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: September 21, 2021
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Ho-Young Lee, Hye-Young Min, Hye-Jin Boo, Hyun-Ji Jang
  • Compounds, compositions, and methods for treating human immunodeficiency virus
    Patent number: 11116762
    Abstract: Disclosed herein are compounds useful for treating and/or preventing HIV infections and the transmission of HIV from an infected subject.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: September 14, 2021
    Assignee: OyaGen, Inc.
    Inventors: Harold C. Smith, Ryan P. Bennett
  • Use of substituted benzylideneguanidine derivatives as synergists for polymyxin antibiotics
    Patent number: 11116735
    Abstract: A use of a substituted benzoguanidine derivative as a polymyxin antibiotic synergist, particularly as a synergist and a drug resistance reversal agent of the polymyxin antibiotic for inhibiting a sensitive strain, or a composition comprising the same in combination with a polymyxin antibiotic for preparing a compound pharmaceutical preparation for human or animal use in the treatment of a disease caused by a gram-negative bacterial infection or the preparation a growth-promoting feed additive and for the raising of livestock animals.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: September 14, 2021
    Assignee: GUANGZHOU INSIGHTER BIOTECHNOLOGY CO., LTD.
    Inventors: Xianfeng Peng, Zonghua Qin
  • Methods and medicaments for the treatment of renal cell carcinoma
    Patent number: 11110098
    Abstract: The present disclosure is directed, among other things, to the surprising and unexpected efficacy provided by select V2R antagonists in significantly reducing the cell proliferation levels of clear cell renal cell carcinoma. Thus, the present disclosure provides methods, uses, and medicaments that include such select V2R antagonists for utility in treating clear cell renal cell carcinoma.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: September 7, 2021
    Assignee: University of Kansas
    Inventor: Reena Rao
  • Composition for external use on skin for inflammatory diseases
    Patent number: 11103476
    Abstract: [Problem] To provide a composition for external skin use that has anti-inflammatory and antiallergic activity, and is very safe. [Solution] A composition for external skin use for inflammatory diseases contains dihomo-gamma-linolenic acid (DGLA) as the active ingredient thereof. It is preferable for the DGLA to be present as a glyceride, a phospholipid, or an alkyl ester. The amount of DGLA contained in the composition for external use is 0.1-50 wt %.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: August 31, 2021
    Assignee: NIPPON SUISAN KAISHA, LTD.
    Inventors: Jiro Takeo, Hiroyuki Kawahara
  • MAP2K1 (MEK1) as a therapeutic target for arteriovenous malformations and associated disorders
    Patent number: 11104955
    Abstract: The instant disclosure provides methods and compositions related to discovery of MAP2K (MEK1) as a therapeutic target for treatment or prevention of arteriovenous malformations (AVMs). Therapeutic and/or prophylactic uses and compositions of known MEK1 inhibitors, including small molecules and nucleic acid agents, are described.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: August 31, 2021
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arin K. Greene, Matthew Warman, Yue Huang
  • ALK and NTRK1 fusion molecules and uses thereof
    Patent number: 11098368
    Abstract: Novel ALK and NTRK1 fusion molecules and uses are disclosed.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: August 24, 2021
    Assignee: FOUNDATION MEDICINE, INC.
    Inventors: Maureen T. Cronin, Doron Lipson, Roman Yelensky
  • Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer
    Patent number: 11090311
    Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: August 17, 2021
    Assignee: Board of Regents, the University of Texas System
    Inventors: Thomas J. Slaga, Jacob Junco, Huiyun Liang, Sara Reyna